Join the Cobenfy group to help and get support from people like you.
Cobenfy News
FDA Approves Cobenfy for Adults With Schizophrenia
THURSDAY, Nov. 14, 2024 – The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in...
FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and...
FDA Approves Cobenfy, a New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 – The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and Drug Administration. Cobenfy...